SBIR PHASE I

October 1, 2018

Development of a metabolomics and machine learning based high-throughput screening platform for data-driven drug discovery with Sinopia Biosciences

This grant combines Omix’s exceptional ability to generate metabolomics data with unprecedented throughput, accuracy and precision with Sinopia’s proven history of expertise in computation analysis of metabolomics data. This combination will allow for studying drug-like compounds’ effects on cellular systems at a deeper level of biochemical detail than before, with applications in drug discovery, drug repurposing, and drug safety.

SBIR PHASE II

June 22, 2017

PLT storage additives in collaboration with Sinopia Bioscience

"Improving the safety and efficacy of platelet transfusion through systems biology", an award for approximately $1.5 million, will support the deployment of Sinopia's platform for platelet transfusion products. As a subcontractor, the multi-center project will strengthen existing key collaborations between Omix Technologies and Sinopia Biosciences.

SBIR Phase II

August 24, 2016

RBC storage additives in collaboration with Sinopia Bioscience

"Improving red blood cell transfusion through systems biology", an award for approximately $1.5 million, will support the experimental deployment of Sinopia's platform for transfusion medicine. Omix Technologies will support this Phase II grant, which focuses on testing novel additives that combat metabolic changes during blood bank storage in order to better preserve red blood cells for transfusion. 

SBIR phase II

February 22, 2016

Omix Technologies supports development of Hemanext

The metabolomics and proteomics platform of Omix Technologies will be used as a supportive development tool to optimize Hemanext, the anaerobic storage approach developed by New Health Sciences, Inc.